Estimations des analystes de Wall Street pour Agios Pharmaceuticals, Inc. (AGIO): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-10-29 | $-1.21 | ||
| 2026-07-30 | $-1.69 | $-1.65 | -2.4% |
| 2026-04-29 | $-1.69 | $-1.81 | +6.6% |
| 2026-02-12 | $-1.85 | $-1.97 | +6.1% |
| 2025-10-30 | $-1.78 | $-1.93 | +7.8% |
| 2025-07-31 | $-1.93 | $-1.74 | -10.9% |
| 2025-05-01 | $-1.55 | $-1.80 | +13.9% |
| 2025-02-13 | $-1.74 | $-1.69 | -3.0% |
Ratios de valorisation
| Prix / Valeur comptable | 1.95 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $69.9M | $43.0M | $94.4M | $117.9M | 0 | 0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Coût des Ventes | $220.2M | $292.7M | $1.4M | $1.3M | $18.8M | $18.8M | $1.7M | $9.5M | $4.2M | $11.5M |
| Marge Brute | -$150.3M | -$249.7M | $93.0M | $116.6M | -$18.8M | -$18.8M | $12.5M | $17.3M | $32.3M | $42.5M |
| R&D | $220.2M | $292.7M | $341.3M | $410.9M | $211.0M | $257.0M | $279.9M | $288.9M | $301.3M | $334.4M |
| Frais Généraux | $50.7M | $71.1M | $114.1M | $132.0M | $106.1M | $121.4M | $121.7M | $119.9M | $156.8M | $180.3M |
| Charges Opérationnelles | $270.9M | $363.8M | $455.5M | $542.9M | $317.1M | $359.6M | $401.6M | $408.8M | $458.1M | $514.6M |
| Résultat Opérationnel | -$201.0M | -$320.8M | -$362.5M | -$426.3M | -$335.9M | -$378.4M | -$389.0M | -$391.5M | -$425.7M | -$472.1M |
| EBITDA | -$195.3M | -$314.4M | -$338.9M | -$394.9M | -$310.5M | -$337.7M | -$223.2M | -$345.5M | $723.6M | -$408.6M |
| Charges d'Intérêt | 0 | 0 | 0 | 0 | $17.8M | 0 | 0 | 0 | 0 | 0 |
| Résultat Avant Impôts | -$198.5M | -$314.7M | -$346.0M | -$411.5M | -$329.3M | -$356.5M | -$231.8M | -$352.1M | $718.0M | -$413.8M |
| Impôts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $44.2M | -$1.0M |
| Résultat Net | -$198.5M | -$314.7M | -$346.0M | -$411.5M | -$327.4M | $1.60B | -$231.8M | -$352.1M | $673.7M | -$412.8M |
| BPA | $-5.07 | $-6.75 | $-6.03 | $-6.61 | $-4.74 | $-6.36 | $-4.23 | $-6.33 | $11.86 | $-7.12 |
| BPA Dilué | $-5.07 | $-6.75 | $-6.03 | $-6.61 | $-4.74 | $-6.36 | $-4.23 | $-6.33 | $11.64 | $-7.12 |
| Actions en Circulation (Diluées) | $39.1M | $46.6M | $57.4M | $60.0M | $69.0M | $60.4M | $54.8M | $55.7M | $57.9M | $58.0M |
Prix
| Prix | $33.61 |
| Capitalisation | $2.0B |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: BEAM · COGT · DNLI · ETNB · GLPG · IBRX · LQDA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de AGIO: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions